StoxDivi's Laboratories vs Zydus Lifesciences: share price & financials comparison
NSE: DIVISLAB vs ZYDUSLIFE · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Divi's Laboratories vs Zydus Lifesciences at a glance
Divi's Laboratories (DIVISLAB) has a market capitalisation of ₹3,03,213 Cr, against ₹1,18,752 Cr for Zydus Lifesciences (ZYDUSLIFE). Over the past year Divi's Laboratories has returned +68.2%, compared with +22.5% for Zydus Lifesciences. On valuation, Zydus Lifesciences trades at a lower P/E of 28.4 versus 90.2. Divi's Laboratories earns a higher return on equity (18.7% vs 15.0%). Divi's Laboratories comes out ahead on profitability, growth, momentum and technicals. Zydus Lifesciences comes out ahead on size and valuation. Across the scored metrics below, Divi's Laboratories leads on 11 and Zydus Lifesciences on 6. On StoxGud's 10-point checklist, Divi's Laboratories scores 8/10 and Zydus Lifesciences scores 10/10.
| Metric | Divi's Laboratories | Zydus Lifesciences |
|---|---|---|
| Size | ||
| Market cap | ₹3,03,213 Cr | ₹1,18,752 Cr |
| Revenue (latest FY) | ₹10,560 Cr | ₹27,148 Cr |
| Net profit (latest FY) | ₹2,568 Cr | ₹5,040 Cr |
| Valuation | ||
| P/E | 90.2 | 28.4 |
| P/B | 16.85 | 4.27 |
| Dividend yield | 0.26% | 0.93% |
| Profitability | ||
| Return on equity | 18.7% | 15.0% |
| Net profit margin | 27.6% | 13.8% |
| Operating margin | 38.1% | 27.0% |
| Growth | ||
| Revenue growth (YoY) | +35.4% | +29.2% |
| Net profit growth (YoY) | +63.6% | -26.5% |
| Revenue CAGR (multi-year) | +11.8% | +12.4% |
| Financial health | ||
| Debt to equity | 0.00 | 0.48 |
| Momentum | ||
| 1-month return | +23.2% | +5.1% |
| 1-year return | +68.2% | +22.5% |
| 3-year CAGR | +48.3% | +24.2% |
| 5-year CAGR | +18.5% | +19.3% |
| 10-year CAGR | +25.7% | +12.8% |
| Distance from 52W high | -1.1% | -4.5% |
| Technicals | ||
| RSI (14) | 91 | 63 |
| Price vs 200-day avg | +52.4% | +13.6% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Divi's Laboratories | Zydus Lifesciences |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 8/10 | 10/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Divi's Laboratories or Zydus Lifesciences?
Divi's Laboratories has a market cap of ₹3,03,213 Cr and Zydus Lifesciences has a market cap of ₹1,18,752 Cr as of 13 Nov 2026.
Which has a lower P/E, Divi's Laboratories or Zydus Lifesciences?
Zydus Lifesciences has the lower P/E: Divi's Laboratories trades at 90.2 and Zydus Lifesciences at 28.4.
Which gave better returns in the last year, Divi's Laboratories or Zydus Lifesciences?
Divi's Laboratories did better: Divi's Laboratories returned +68.2% and Zydus Lifesciences returned +22.5% over one year.
What is the difference between Divi's Laboratories and Zydus Lifesciences?
Both are NSE-listed companies in Healthcare. Divi's Laboratories is about 2.6 times the size of Zydus Lifesciences by market cap. In the latest financial year Divi's Laboratories reported revenue of ₹10,560 Cr and Zydus Lifesciences ₹27,148 Cr. Operating margin is 38.1% for Divi's Laboratories and 27.0% for Zydus Lifesciences. Debt to equity is 0.00 for Divi's Laboratories and 0.48 for Zydus Lifesciences.
Which is better, Divi's Laboratories or Zydus Lifesciences?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Divi's Laboratories leads on 11 and Zydus Lifesciences on 6. Divi's Laboratories is ahead on profitability, growth, momentum and technicals. Zydus Lifesciences is ahead on size and valuation. On StoxGud's rules-based checklist Divi's Laboratories scores 8/10 and Zydus Lifesciences scores 10/10. This is information, not advice: consult a SEBI-registered adviser before investing.